Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
about
Future of coagulation factor replacement therapyLessons Learned from Animal Models of Inherited Bleeding Disorders.Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Animal models of hemophilia and related bleeding disorders.Investigational drugs for coagulation disorders.Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.Factor VIII therapy for hemophilia A: current and future issues.Innovative approach for improved rFVIII concentrate.Turoctocog alfa for the treatment of hemophilia a.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies.Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.Simoctocog alfa for the treatment of hemophilia A.Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
P2860
Q26820824-0188C195-10FB-43F4-B70A-25C0E0132A5EQ30409863-0BCC1268-6C35-44DD-95E6-B5A8EDC6C415Q34283156-691A918F-BF0C-453C-B8C2-4938A6FD1899Q36912731-A1C60DD8-908D-4054-BF21-38C8C2213668Q37091290-8D831009-CD5A-4F16-B771-6A32FD74A727Q38106245-1629A8C6-E922-4379-8C71-355E462B0737Q38121644-0EF82986-21E8-4B43-B7F6-08632E101751Q38203350-AE817325-AE64-47A9-B940-BDD8C29E5364Q38207134-ADA822FA-A785-4715-AEFD-EE6FE2F494A5Q38232780-2BF14B78-7C81-4DC6-AC22-0F5AE9F87162Q38371071-0914C80F-937E-495C-BED2-F0311A64AE45Q38754256-3E4B3FED-6800-4269-80A5-0A1B1F8442B4Q40573329-98E175A0-D6F3-4413-ACC4-BBA7365ED0FEQ42220577-BFA1359F-8776-4E53-BB27-AF574ECD3D7AQ45873366-F164DD51-96B9-474A-B999-02F5F66BD1CDQ45884927-6927C127-C5F3-42EF-A0DE-E28C21A006B9Q45887979-A0553B71-FEE3-4EBA-A775-617C97FC49E9Q58583115-3C602B00-D9EF-4D52-BF9F-B63AA0DA8B55
P2860
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
@en
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
@nl
type
label
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
@en
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
@nl
prefLabel
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
@en
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
@en
P2093
E P Merricks
H R Stennicke
N A Defriess
T C Nichols
P2860
P304
P356
10.1111/J.1365-2516.2012.02896.X
P577
2012-07-20T00:00:00Z